Clinical Trial

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Name: A Phase 1 Study of the Safety and Tolerability of CTX-10726 — clinical trial record (NCT07419841)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-02

Trial Details

NCT Number	NCT07419841
Lead Sponsor	Compass Therapeutics
Conditions	Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Enrollment	70 participants
Start Date	2026-05-28
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-31